Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419008 | 0.93 | GPR119 (0.73) | GPR119HDAC4CETPHDAC6LMNA | |
| SCHEMBL4416595 | 0.91 | GPR119 (0.69) | GPR119HDAC4HDAC6SMN1; SMN2 | |
| SCHEMBL4417299 | 0.91 | GPR119 (0.69) | GPR119HDAC4CETPHDAC6PTPN2 | |
| SCHEMBL4421899 | 0.90 | GPR119 (0.68) | GPR119HDAC4HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL4416063 | 0.88 | GPR119 (0.78) | GPR119HDAC4HDAC6LMNAMAPK1 | |
| SCHEMBL4422138 | 0.87 | GPR119 (0.69) | GPR119HDAC4 | |
| SCHEMBL4415988 | 0.86 | GPR119 (0.67) | GPR119HDAC4CETPHDAC6LMNA | |
| SCHEMBL14640607 | 0.85 | GPR119 (0.74) | GPR119HDAC4CETPHDAC6LMNA | |
| SCHEMBL17122217 | 0.84 | GPR119 (0.84) | GPR119HDAC4HDAC6KMT2A | |
| SCHEMBL4415733 | 0.83 | GPR119 (0.69) | GPR119HDAC4HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HDAC4 2550/4885CETP 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.